Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04741230

Investigator Initiated, Prospective Study of Xenia Corneal Lenticule

Cornea ectatic conditions such as keratoconus and post-LASIK (Laser In situ Keratomileusis) ectasia are disorders of the eye that are notorious for its uncontrolled progression over time, leading to loss of vision. There are valuable treatment options for controlling disease progression in mild to moderate stages of such disease. However in advanced cases and / or when contact lenses cannot be worn, surgery remains the only treatment option to rehabilitate vision. Most treatment options are highly invasive and represent significant risks. This study evaluates a novel corneal implant, Gebauer™ Lenticule to treat severe keratoconus or post-LASIK ectasia. This implant is derived from porcine collagen and intended for intra-stromal insertion. The Gebauer™ Lenticule is expected to improve the stability of the cornea while not impairing the vision. The procedure is an additive procedure after other treatment options have been exhausted. The procedure is reversible with removal of the implant (in the unexpected case of an adverse reaction), and vision may be restored to baseline.

The purpose of this study is to evaluate how well the implant is tolerated, it's safety profile, and how effective this new treatment option is in the treatment of keratoconus or post-LASIK ectasia.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–79 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The Royal Wolverhampton NHS Trust

Wolverhampton, West Midlands, WV10 0QP, United Kingdom

Location status: Recruiting

Location contact

B Ilango

CONTACT

[email protected]

01902307999

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of severe keratoconus in patients who would prefer to avoid corneal transplant surgery / penetrating keratoplasty OR
  • Diagnosis of severe post-LASIK Ectasia in patients who would prefer to avoid corneal transplant surgery / penetrating keratoplasty
  • In terms of general health, patients must be free of diagnosed terminal illnesses (life expectancy of greater than or equal to 2 years).
  • Patients must be aged 18 years or over and less than 80 years old
  • Patients' contact lenses must have been removed at least one-week prior to surgery for soft lenses and two weeks prior to surgery for hard lenses
  • Subject understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed
  • Patient must be able and willing to complete all study visits and comply with the study-specific requirements

Exclusion criteria

  • History or presence of any ocular pathologies that may interfere with the planned surgical treatment, including corneal epithelial problems
  • Previous corneal transplantation or corneal implant in the designated eye
  • Cataract with anticipated surgical intervention (IOL implantation) within 2 years
  • Active inflammation and/or infection of the eye or the eye lid
  • Patients with Intra Ocular Pressure (IOP) <10 mmHg or >21 mmHg
  • Professionally diagnosed and currently treated autoimmune diseases
  • Current strong symptoms of any allergy
  • History of major organ transplantation and/or current continuing immunosuppressive treatment
  • History of blood transfusion within the last 12 months
  • Subject who is currently participating or has participated in another investigational clinical study within the past 60 days Pregnancy and lactation

Treatment and study plan

Gebauer Lenticule

Device

The Gebauer™ Lenticule corneal implant device is a custom-made device intended for patients suffering from keratoconus or post-LASIK ectasia. The device is expected to reinforce and stabilize the patient's cornea, so that a more consistent refraction is induced and a penetrating human cornea donor transplantation may be avoided or postponed.

Primary outcomes

  1. Number of participants with Immunological rejection by ophthalmic examination of Intraocular pressure, Best corrected visual acuity, Corneal and Lenticule transparency, Inflammation

    Time frame: 6 months

    Signs of immunological rejection during the post implantation observation period

  2. Treatment-related adverse events.

    Time frame: 6 months

    The frequency and severity of all treatment-related adverse events, during implantation of the Gebauer™ Lenticule and throughout the post implantation observation period.

  3. Changes in corneal topography (central K-reading results)

    Time frame: 6 months

    Changes in corneal topography (central K-reading results): at baseline vs. post implantation observation period

  4. Central corneal thickness

    Time frame: 6 months

    Changes in central corneal thickness at baseline vs. post implantation corneal thickness (cornea plus lenticule)

Study contacts

Contact information is provided by the study sponsor or research team.

B Ilango

CONTACT

[email protected]

01902307999

Sponsors and collaborators

Lead sponsor

The Royal Wolverhampton Hospitals NHS Trust

Other Gov

Collaborators

  • Gebauer Company

Registry information

Official study title

Prospective, Investigator Initiated Feasibility Study to Evaluate the Safety, and Indicative Effectiveness of Gebauer™ Lenticules in Patients Suffering From Severe Keratoconus or Post LASIK Ectasia

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Feb 5, 2021
Registry last updated
Jan 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.